Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: Keytruda | Statement: [Merck & Co., notableDrug, Keytruda]

Target entity: Keytruda
Context triple: [Merck & Co., notableDrug, Keytruda]

• A. Tecentriq
  Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
• B. Imbruvica
  Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
• C. Alimta
  Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
• D. Onpattro
  Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
• E. Inflectra
  Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"

Entity: Keytruda
Triple: [Merck & Co., notableDrug, Keytruda]

Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.

Target entity: Keytruda
Target entity description: Keytruda is a widely used immunotherapy cancer drug (pembrolizumab) that works by blocking the PD-1 pathway to help the immune system attack tumors.

• A. Tecentriq
  Tecentriq is an immunotherapy cancer drug (atezolizumab) that targets the PD-L1 protein to help the immune system attack tumors in various cancers.
• B. Imbruvica
  Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
• C. Alimta
  Alimta is a chemotherapy drug (pemetrexed) primarily used to treat malignant pleural mesothelioma and non-small cell lung cancer.
• D. Onpattro
  Onpattro is an RNA interference (RNAi) therapeutic used to treat polyneuropathy in adults with hereditary transthyretin-mediated (hATTR) amyloidosis.
• E. Inflectra
  Inflectra is a biosimilar monoclonal antibody to infliximab used to treat autoimmune inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, and ulcerative colitis.
• F. None of above. chosen

Target predicate: notableDrug
Context triple: [Merck & Co., notableDrug, Keytruda]

• A. hasNotableDrug chosen
  Indicates that an entity is associated with a drug that is considered notable or significant in some recognized context.
• B. usesDrug
  Indicates that an entity consumes, administers, or otherwise makes use of a specified drug.
• C. drugClass
  Indicates that one entity is classified as a particular pharmacological or therapeutic category of drugs in relation to another entity.
• D. protectedDrugClassesInclude
  Indicates that the specified set of protected drug classes includes the referenced drug class or classes.
• E. notableSubstanceReleased
  Indicates that an entity has released or emitted a particular notable substance.
• F. None of above.